IP Verse

Injectable Long-Acting Naltrexone Microparticle Compositions - EP3866765

The patent EP3866765 was granted to Chong KUN Dang Pharmaceutical on Feb 7, 2024. The application was originally filed on Oct 15, 2019 under application number EP19874338A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3866765

CHONG KUN DANG PHARMACEUTICAL
Application Number
EP19874338A
Filing Date
Oct 15, 2019
Status
Granted And Under Opposition
Jan 5, 2024
Grant Date
Feb 7, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALKERMES PHARMA IRELANDNov 6, 2024ATKINSADMISSIBLE

Patent Citations (20) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONCN100379420C
DESCRIPTIONCN101700226
DESCRIPTIONCN1415294
DESCRIPTIONUS6306425
DESCRIPTIONUS7157102
DESCRIPTIONUS7279579
DESCRIPTIONUS7914804
DESCRIPTIONUS7919499
DESCRIPTIONUS8343528
DESCRIPTIONWO2017033208
INTERNATIONAL-SEARCH-REPORTCN1415294
INTERNATIONAL-SEARCH-REPORTEP1786400
INTERNATIONAL-SEARCH-REPORTUS2015265535
INTERNATIONAL-SEARCH-REPORTUS7799345
INTERNATIONAL-SEARCH-REPORTWO2009058147
OPPOSITIONUS2005245558
OPPOSITIONUS6264987
SEARCHCN100379420C
SEARCHCN101700226
SEARCHCN1415294

Non-Patent Literature (NPL) Citations (12) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "VIVITROL TM (naltrexone for extended-release injectable suspension) - package insert", (20051111), XP093249040
OPPOSITION- BARTUS R T, ET AL., "Vivitrex, an Injectable, Extended-Release Formulation of Naltrexone, Provides Pharmacokinetic and Pharmacodynamic Evidence of Efficacy for 1 Month in Rats.", Neuropsychopharmacology, Springer International Publishing, Cham, Cham, (20031101), vol. 28, no. 11, ISSN 0893-133X, pages 1973 - 1982, XP002992765
OPPOSITION- Richard A Graves, Sarala Pamujula, Raisa Moiseyev, Thomas Freeman, Levon A Bostanian, Tarun K Mandal, "Effect of different ratios of high and low molecular weight PLGA blend on the characteristics of pentamidine microcapsules", International Journal of Pharmaceutics, Elsevier, (20040201), vol. 270, no. 1-2, doi:10.1016/j.ijpharm.2003.10.019, ISSN 03785173, pages 251 - 262, XP055144798
OPPOSITION- Wischke, C. ; Schwendeman, S.P., "Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles", International Journal of Pharmaceutics, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL, (20081208), vol. 364, no. 2, doi:10.1016/j.ijpharm.2008.04.042, ISSN 0378-5173, pages 298 - 327, XP025669766
OPPOSITION- Goonoo Nowsheen; Bhaw-Luximon Archana; Ujoodha Reetesh; Jhugroo Anil; Hulse Gary K.; Jhurry Dhanjay, "Naltrexone: A review of existing sustained drug delivery systems and emerging nano-based systems", Journal of Controlled Release, Elsevier, NL, NL , (19000101), vol. 183, doi:10.1016/j.jconrel.2014.03.046, ISSN 0168-3659, pages 154 - 166, XP028648109
OPPOSITION- Judith P. Kitchell , Donald L. Wise, "[32] Poly(lactic/glycolic acid) biodegradable drug—polymer matrix systems", Drug and Enzyme Targeting Series title: Methods in Enzymology, United States, Elsevier Science & Technology, (19850101), vol. 112, pages 436 - 448, doi:10.1016/S0076-6879(85)12034-3, ISSN 0076-6879, ISBN 0121820122, XP009559379
OPPOSITION- ANDERSON J.M., SHIVE M S, "Biodegradation and biocompatiblity of PLA and PLGA microspheres", Advanced Drug Delivery Reviews, Elsevier, Amsterdam , NL, Amsterdam , NL , (19970101), vol. 28, doi:10.1016/S0169-409X(97)00048-3, ISSN 0169-409X, pages 5 - 24, XP002249688
OPPOSITION- Xuyi Wang, Juelu Wang, Xiaojun Xiang, Haiyan Li, Zheyuan Liu, Zhehui Gong, Guoming Dong, Gang Liu, Jin Li, Wei Hao, "Phase I study of injectable, depot naltrexone for the relapse prevention treatment of opioid dependence", AMERICAN JOURNAL OF ADDICTIONS, AMERICAN PSYCHIATRIC PRESS, WASHINGTON, DC,, US, US , (20140301), vol. 23, no. 2, doi:10.1111/j.1521-0391.2013.12085.x, ISSN 1055-0496, pages 162 - 169, XP093249044
OPPOSITION- Galloway Gantt P; Koch Monika; Cello Ryan; Smith David E, "Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial", BMC PSYCHIATRY, BIOMED CENTRAL, LONDON, GB, GB , (20050401), vol. 5, no. 1, doi:10.1186/1471-244X-5-18, ISSN 1471-244X, page 18, XP021005133
OPPOSITION- Emmamuel O Akala et al, "Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres", Journal Drug Development and Industrial Pharmacy, NEW YORK, NY, US, US , (20110630), vol. 37, no. 6, doi:10.3109/03639045.2010.535540, ISSN 0363-9045, pages 673 - 684, XP055714626
OPPOSITION- JAIN R, ET AL., "CONTROLLED DRUG DELIVERY BY BIODEGRADABLE POLY(ESTER) DEVICES: DIFFERENT PREPARATIVE APPROACHES", Journal Drug Development and Industrial Pharmacy, NEW YORK, NY, US, US , (19980101), vol. 24, no. 08, doi:10.3109/03639049809082719, ISSN 0363-9045, pages 703 - 727, XP009052301
SEARCH- YAMAGUCHI K. ET AL., "Biocompatibility studies of naltrexone sustained release formulations", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 19, no. 1-3, doi:10.1016/0168-3659(92)90085-6, ISSN 0168-3659, (19920301), pages 299 - 314, (19920301), XP023744411 [X] 1-15 * figures 9-11 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents